explore -WSS

explore

author：fashion 2025-09-06 03:57:06 - browse：34541

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Pfizer, Moderna say biotech, pharma drug development is a sprint

WSS

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Reports of telehealth's death have been greatly exaggerated

CRISPR technology availability, affordability needs to be expanded

With Wegovy coverage, Medicare patients may face high costs

With Wegovy coverage, Medicare patients may face high costs

Steward Health Care expansion into Malta flopped

focus

explore

knowledge

ChatGPT in medicine: STAT answers readers' burning questions

Diabetes management: Digital health tools fall short, study says

Medical leaders decry Supreme Court decision on affirmative action

Digital health: a case of mistaken identity

Walensky prepares to leave CDC — and Congress — behind

Testing GLP

The high cost of giving birth even with insurance

Cancer, immunology, HIV research ensnared in fetal tissue politics

ChatGPT in medicine: STAT answers readers' burning questions

Listen: More tumult at BIO & coercive care for sickle cell patients

focus

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

This gene therapy has record $4.25 million price. It's saved children.

CRISPR technology availability, affordability needs to be expanded

Questions and answers about ramping up H5N1 bird flu vaccine

CRISPR technology availability, affordability needs to be expanded

hotspot

Wikipedia

hotspot

Wikipedia